96% SVR4 in noncirrhotic NS5A-experienced patients receiving 12-week, RBV-free regimen.
Among 3 patients who relapsed without achieving SVR12, all had resistance associated substitutions.
SVR12 rate of 96% in population where majority had ongoing drug use and/or were receiving opiate substitution therapy.
Fewer relapses with inclusion of RBV, particularly in patients with baseline NS5A RAS.
Overall SVR12 rate of 96% with no study drug–related serious adverse events at interim analysis.
Patients also maintained HBV DNA suppression following switch from TDF to TAF.